Latest funding announcements | November 2017

MTP Connect is accepting applications for funding under the MRFF Biotech Horizons Program. Funding of $3 million is available for precision medicine and $2 million for 3D printing. Expressions of interest will be open until 10 December 2017. More information is available at MTP Connect.

MRFF disbursements for 2017/18

  • $70 million over 5 years from 2017/18 for the Next Generation Clinical Researchers Program. $10 million of this will be available from the 2017/18 disbursements for Fellowships commencing in 2019, rising to $20 million in subsequent years. This funding is in addition to the $8 million in funding for Fellowships announced in 2016/17, and which commence in 2018.
  • $50 million from the MRFF, to be matched dollar for dollar by philanthropy will be available over multiple years from 2017/18 for the Australian Brain Cancer Mission. Prioritised first investments include the establishment of an Australian arm of the GBM AGILE, an international adaptive trial platform for adults with glioblastoma, new funding for Australian and New Zealand Children’s Haematology Oncology Group (ANZCHOG) clinical trial centres, and support for the consolidation of the national ZERO Children’s Cancer initiative.
  • A further $30 million in funding will be allocated over the next four financial years. This builds on the initial $5 million allocated in 2016/17 which is being administered by MTPConnect and is currently open for Expressions of Interest. Investments from the program will be focused on supporting cutting-edge ideas in precision medicine and 3D anatomical printing towards proof-of-concept and commercialisation.

MRFF disbursements for 2016/17

$65.9 million is available for 2016/17; all of the programs have been announced and there are now calls for applications for some programs, with two more to come.

  • $8 million is to be allocated across the four pre-existing NHMRC Advanced Health Research Translation Centres (something Research Australia has advocated for over a year). Of this amount, Monash Partners AHRTC is receiving $2 million for research and initiatives to improve care in blood and lung cancer, cardiovascular disease diabetes dementia, and improve influenza vaccination rates. Sydney Health Partners AHRTC has been allocated $2.2 million for three programs, to address lower back pain, improve recruitment for clinical trials, and address gaps in the health system.  Detail of the other AHRTCs’ research programs has yet to be announced.
  • $2 million to support new and existing Advanced Health Research and Translation Centres (AHRTCs) and the two soon-to-be-announced Centres for Innovation in Regional Health (CIRHs) to work together on national system-level initiatives. Of this amount, $225,000 has been allocated to the recently announced Dimantina Partners AHRTC, and $225,000 to the newly announced The SPHERE (Sydney Partnership for Health, Education, Research and Enterprise) AHRTC. A further $225,000 has been allocated to NSW Regional Health Partners, a freshly minted CIRH.
  • $10 million in funding will be provided to The Australian Prevention Partnership Centre (TAPCC) to generate effective low-cost solutions to address chronic disease and childhood obesity.
  • $5 million for new targeted clinical trial activity for adolescents and young adults with cancer, to be administered by CanTeen.
  • $13 million over four years to increase clinical trials and registries’ capacity. This includes funding for networks of investigators and service providers that work together, to identify and evaluate new approaches that will optimise healthcare effectiveness. (Targeted call for funding applications being administered by NHMRC, with funding to commence in January 2018.)
  • $5 million over four years to the Australian Clinical Trials Alliance (ACTA) as the national alliance partner to build the capacity of clinical trials networks.
  • $8 million to boost the scale of three existing NHMRC Fellowship schemes- Career Development Fellowships, (early to mid-career researchers in clinical, population health, biomedical and bioinformatics fields); Translating Research into Practice Fellowships (health professionals translating evidence into healthcare and public health improvements) and Practitioner Fellowships (implementing evidence-based practice among clinical, public health and health service professionals). Fellowship awards will be announced from early 2017-18.
  • $2 million to the Coalition for Epidemic Preparedness Innovations (CEPI), a new international initiative to address critical research and development gaps for pandemic preparedness and global health security.
  • $5.9 million for antimicrobial resistance to address knowledge gaps in relation to the development and spread of resistance; and the development of new products, including diagnostic technologies and therapies, policies and approaches to prevent, detect and respond to resistance. (Targeted call for funding applications being administered by NHMRC, with funding to commence in January 2018.)
  • $5 million to establish the Biotech Horizons program, to provide early stage pre-clinical support for biotechnologies.
  • $2 million to Cure4MND for clinical trials for adults with MND. This amount was provided as matching funding to public donations to Cure4MND’s ‘Big Freeze 3’ fundraising campaign.